Company Profile — Nissan Chemical Corporation (4021.T), founded in 1887 by Meiji-era industrialists Jokichi Takamine and Eiichi Shibusawa as Japan's first synthetic fertilizer company, has transformed over 137 years into a high-margin specialty chemicals leader generating ¥251B in annual sales across 3,283 employees. The company operates two structural pillars: semiconductor-grade functional materials—including high-purity sulfuric acid and photoresist underlayer films critical to advanced chip fabrication—and agrochemicals, providing recession-resistant cash flow balance. Operating margins exceeding 22% place Nissan Chemical decisively above Japanese chemical sector medians of approximately 8%, reflecting proprietary formulation technology and captive customer relationships with leading semiconductor fabs. Vista2027 Stage II targets ¥293B in sales and ¥65B operating profit by FY2027, with M&A explicitly authorized in functional materials and agrochemicals segments.

Business Performance — FY2025 sales rose 10.6% YoY to ¥251B with operating income surging 18.8% to ¥57B, driving net income to ¥43B and EPS to ¥313. ROE reached 18.7%, recovering from the FY2024 trough of 17.1% and approaching the FY2023 peak of 19.4%. Management raised DPS to ¥174 (payout ratio 65%), executed ¥9B in programmatic buybacks including cancellation of 1,000,000 shares in March 2026, while holding capex to ¥18B. The single most important trend is the five-year ROE corridor of 17–19%, demonstrating structural rather than cyclical profitability.

Material Note — Vista2027 Stage I missed new-product sales targets by approximately 45%; Stage II launched April 2025 with ¥65B operating profit target, and strategic holding unwind pressure from SMTB (8.1% stake) and Mizuho under TSE reform could fuel EPS-accretive buybacks.

Investment Thesis

• High-purity sulfuric acid and photoresist underlayer films embedded in leading global semiconductor fab supply chains
• Agrochemicals segment provides counter-cyclical cash flow, balancing semiconductor capex-cycle exposure
• Operating margin >22% versus Japanese chemical sector median ~8%, reflecting proprietary formulation IP
• ¥59B OCF in FY2025 and ~70% equity ratio provide M&A capacity explicitly authorized under Vista2027 Stage II